Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumors”

101 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 101 results

Early research (Phase 1)Active Not RecruitingNCT04750954
What this trial is testing

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Neoplasm
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Large-scale testing (Phase 3)Study completedNCT02608203
What this trial is testing

[68 Ga]-DOTANOC PET/CT in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Assistance Publique Hopitaux De Marseille 18
Testing effectiveness (Phase 2)WithdrawnNCT03901378
What this trial is testing

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungHigh Grade Neuroendocrine Carcinoma, Any Site
Ochsner Health System
Early research (Phase 1)Ended earlyNCT05364944
What this trial is testing

Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
AcromegalyGEP-NET
Debiopharm International SA 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT06790706
What this trial is testing

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Who this might be right for
Peritoneal MesotheliomaGestational Trophoblastic TumorAnaplastic Thyroid Carcinomas+3 more
Hospices Civils de Lyon 27
Early research (Phase 1)Study completedNCT05262556
What this trial is testing

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine NeoplasmNeuroendocrine Carcinoma+1 more
Amr Mohamed MD 15
Not applicableStudy completedNCT06853457
What this trial is testing

A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Who this might be right for
Neuroendocrine Tumors, NET
First Affiliated Hospital, Sun Yat-Sen University 257
Not applicableUnknownNCT06402695
What this trial is testing

Observational Study on GEP-and Pulm-NET Treated at FPG

Who this might be right for
Neuroendocrine TumorsGep NetPulmonary Neuroendocrine Neoplasm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 650
Testing effectiveness (Phase 2)Study completedNCT02231762
What this trial is testing

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 57
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784
What this trial is testing

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more
University of Washington 20
Testing effectiveness (Phase 2)Looking for participantsNCT05048901
What this trial is testing

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan 49
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic Neuroendocrine Prostate Cancer+8 more
SystImmune Inc. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more
Novartis Pharmaceuticals 116
Not applicableStudy completedNCT04696042
What this trial is testing

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Asan Medical Center 71
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Next Page
116